Pantoprazol Sandoz (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Sandoz, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Sandoz is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosive lesions and prevents further damage. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

Pantoprazol Sandoz may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation causing reduced urine output. - Severe hypersensitivity: rash, itching, swelling or anaphylaxis. - Osteoporosis‑related fractures: increased risk of hip, wrist or vertebral fractures with long‑term use. - Vitamin B12 deficiency: low levels leading to fatigue or neuropathy. - Liver enzyme elevation: abnormal liver function test results.

Before initiating therapy with Pantoprazol Sandoz, consider the following safety points: - Assess renal function: adjust use in severe renal impairment. - Review hepatic status: use with caution in moderate to severe liver disease. - Evaluate fracture risk: long‑term therapy may affect bone density. - Monitor for infections: prolonged acid suppression can increase risk of gastrointestinal infections. - Pregnancy and lactation: prescribe only if the potential benefit outweighs risk. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Sandoz can affect the pharmacokinetics of several co‑administered medicines. Awareness of these interactions helps optimise therapy.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption and efficacy. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing thrombotic risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Methotrexate: higher systemic exposure, especially at high doses. - Digoxin: slight increase in serum levels, warranting periodic checks.